Back to Journals » International Journal of Nanomedicine » Volume 16

Immunoassay-Amplified Responses Using a Functionalized MoS2-Based SPR Biosensor to Detect PAPP-A2 in Maternal Serum Samples to Screen for Fetal Down’s Syndrome

Authors Chiu NF, Tai MJ, Nurrohman DT, Lin TL, Wang YH, Chen CY

Received 11 December 2020

Accepted for publication 15 March 2021

Published 9 April 2021 Volume 2021:16 Pages 2715—2733


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Yan Shen

Nan-Fu Chiu,1,2 Ming-Jung Tai,1 Devi Taufiq Nurrohman,1,3 Ting-Li Lin,1 Ying-Hao Wang,1 Chen-Yu Chen4,5

1Laboratory of Nano-Photonics and Biosensors, Institute of Electro-Optical Engineering, National Taiwan Normal University, Taipei City, Taiwan; 2Department of Life Science, National Taiwan Normal University, Taipei City, Taiwan; 3Department of Electronics Engineering, State Polytechnic of Cilacap, Cilacap, Indonesia; 4Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei City, Taiwan; 5Department of Medicine, Mackay Medical College, Taipei City, Taiwan

Correspondence: Nan-Fu Chiu
Laboratory of Nano-Photonics and Biosensors, Institute of Electro-Optical Engineering, National Taiwan Normal University, No. 88, Sec. 4, Ting-Chou Road, Taipei City, 11677, Taiwan
Tel +886-2-77496722
Fax +886-2-86631954
Email [email protected]
Chen-Yu Chen
Department of Obstetrics and Gynecology, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Road, Taipei City, 10449, Taiwan
Tel +886-2-25433535
Fax +886-2-25433642
Email [email protected]

Background: Due to educational, social and economic reasons, more and more women are delaying childbirth. However, advanced maternal age is associated with several adverse pregnancy outcomes, and in particular a high risk of Down’s syndrome (DS). Hence, it is increasingly important to be able to detect fetal Down’s syndrome (FDS).
Methods: We developed an effective, highly sensitive, surface plasmon resonance (SPR) biosensor with biochemically amplified responses using carboxyl-molybdenum disulfide (MoS2) film. The use of carboxylic acid as a surface modifier of MoS2 promoted dispersion and formed specific three-dimensional coordination sites. The carboxylic acid immobilized unmodified antibodies in a way that enhanced the bioaffinity of MoS2 and preserved biorecognition properties of the SPR sensor surface. Complete antigen pregnancy-associated plasma protein-A2 (PAPP-A2) conjugated with the carboxyl-MoS2-modified gold chip to amplify the signal and improve detection sensitivity. This heterostructure interface had a high work function, and thus improved the efficiency of the electric field energy of the surface plasmon. These results provide evidence that the interface electric field improved performance of the SPR biosensor.
Results: The carboxyl-MoS2-based SPR biosensor was used successfully to evaluate PAPP-A2 level for fetal Down’s syndrome screening in maternal serum samples. The detection limit was 0.05 pg/mL, and the linear working range was 0.1 to 1100 pg/mL. The women with an SPR angle > 46.57 m° were more closely associated with fetal Down’s syndrome. Once optimized for serum Down’s syndrome screening, an average recovery of 95.2% and relative standard deviation of 8.5% were obtained. Our findings suggest that carboxyl-MoS2-based SPR technology may have advantages over conventional ELISA in certain situations.
Conclusion: Carboxyl-MoS2-based SPR biosensors can be used as a new diagnostic technology to respond to the increasing need for fetal Down’s syndrome screening in maternal serum samples. Our results demonstrated that the carboxyl-MoS2-based SPR biosensor was capable of determining PAPP-A2 levels with acceptable accuracy and recovery. We hope that this technology will be investigated in diverse clinical trials and in real case applications for screening and early diagnosis in the future.

Keywords: carboxyl-functionalized molybdenum disulfide, carboxyl-MoS2, surface plasmon resonance, SPR, pregnancy-associated plasma protein A2, PAPP-A2, Down’s syndrome, DS, fetal Down’s syndrome, FDS

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]